Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (313) Arrow Down
Filter Results: (313) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (1,340)
    • Faculty Publications  (313)

    Show Results For

    • All HBS Web  (1,340)
      • Faculty Publications  (313)

      multinational pharmaceutical companyRemove multinational pharmaceutical company →

      ← Page 7 of 313 Results →

      Are you looking for?

      →Search All HBS Web
      • June 2015
      • Case

      Ethiopia: An Emerging Market Opportunity?

      By: John A. Quelch and Sunru Yong
      This case centers on the potential and challenges of entering an emerging market. It provides a brief overview of the Ethiopian market, market reforms and policies, and the business environment faced by foreign companies. Three multinational businesses, CareCo, ShoeCo,... View Details
      Keywords: Multinational Firms and Management; Emerging Markets; Foreign Direct Investment; Ethiopia
      Citation
      Educators
      Purchase
      Related
      Quelch, John A., and Sunru Yong. "Ethiopia: An Emerging Market Opportunity?" Harvard Business School Brief Case 915-501, June 2015.
      • May 2015
      • Case

      Transforming Alkermes into a Global Biopharmaceutical Company

      By: C. Fritz Foley and Nicholas Haas
      In the summer of 2011, Jim Frates, CFO of Alkermes faced choices about how to finance the acquisition of Dublin, Ireland-based Elan Drug Technologies (EDT)—a deal that was expected to close in the fall. The case describes the history of Alkermes, provides information... View Details
      Keywords: Financing; Debt; Merger; CFO; Financial Management; Pharmaceutical Industry; Pharmaceutical Industry; United States; Europe
      Citation
      Educators
      Purchase
      Related
      Foley, C. Fritz, and Nicholas Haas. "Transforming Alkermes into a Global Biopharmaceutical Company." Harvard Business School Case 215-079, May 2015.
      • March 2015 (Revised September 2016)
      • Case

      Terrapin Laboratory

      By: Richard G. Hamermesh and Joseph B. Fuller
      Describes the formation and rapid growth of a drug testing company. The company needs to decide whether to enter the painkiller testing market, in addition to growing its drug treatment center business. The associated teaching materials provide students the opportunity... View Details
      Keywords: Business Growth; Entrepreneurial Management; Entrepreneurship; Growth Strategy; Market Entry; Venture Capital; Growth Management; Expansion; Financing and Loans; Health Care and Treatment; Health Testing and Trials; Business Startups; Pharmaceutical Industry; Pharmaceutical Industry
      Citation
      Educators
      Purchase
      Related
      Hamermesh, Richard G., and Joseph B. Fuller. "Terrapin Laboratory." Harvard Business School Case 315-098, March 2015. (Revised September 2016.)
      • February 2015 (Revised November 2015)
      • Supplement

      Building an Integrated Biopharma Company: Crucell (B)

      By: Richard G. Hamermesh, Marianne Van Der Steen and Susan Harmeling
      The Crucell (B) case updates events at Crucell since 2009. In September, 2009, Johnson & Johnson acquired 18% of Crucell for $400 million. This investment was part of a business development deal. Subsequently, in 2012, Johnson & Johnson acquired Crucell for $2.8... View Details
      Keywords: Biotechnology; Biopharmacy Company; Licensing Agreements In Biopharmacy; Licensing; Human Cell-line Technology; Vaccine; Healthcare Innovation; Global Health; Entrepreneurship; Health Care and Treatment; Acquisition; Innovation and Invention; Pharmaceutical Industry; Pharmaceutical Industry
      Citation
      Purchase
      Related
      Hamermesh, Richard G., Marianne Van Der Steen, and Susan Harmeling. "Building an Integrated Biopharma Company: Crucell (B)." Harvard Business School Supplement 815-086, February 2015. (Revised November 2015.)
      • February 2015 (Revised November 2015)
      • Case

      Building an Integrated Biopharma Company: Crucell (A)

      By: Richard G. Hamermesh, Marianne Van Der Steen and Susan S. Harmeling
      By 2009, Crucell had become the largest biopharma company in the Netherlands and a symbol of national pride. The case traces the evolution of the company from a University spin-off into a fully-integrated company. Crucell's success, particularly in the vaccine space,... View Details
      Keywords: Biotechnology; Biopharmacy Company; Licensing; Licensing Agreements In Biopharmacy; Human Cell-line Technology; Vaccine; Healthcare Innovation; Global Health; Partners and Partnerships; Entrepreneurship; Growth and Development Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Netherlands
      Citation
      Educators
      Purchase
      Related
      Hamermesh, Richard G., Marianne Van Der Steen, and Susan S. Harmeling. "Building an Integrated Biopharma Company: Crucell (A)." Harvard Business School Case 815-085, February 2015. (Revised November 2015.)
      • January–February 2015
      • Article

      Heroic Villains: Are Foreign Investors Problems or Solutions in the Ebola Crisis?

      By: Debora L. Spar
      For months, the news out of West Africa has been unrelentingly grim. As of early December, the devastating Ebola epidemic had infected a reported 17,942 people and killed 6,388, according to the World Health Organization (WHO); the actual toll, which would also account... View Details
      Keywords: Ebola; Multinational Corporation; Epidemics; Foreign Investment; Extractive Industries; Multinational Firms and Management; Health Pandemics; Developing Countries and Economies; Government and Politics; Africa
      Citation
      Find at Harvard
      Related
      Spar, Debora L. "Heroic Villains: Are Foreign Investors Problems or Solutions in the Ebola Crisis?" Foreign Policy 210 (January–February 2015).
      • December 2014 (Revised October 2017)
      • Case

      Social Business at Novartis: Arogya Parivar

      By: Michael E. Porter, Mark R. Kramer and David Lane
      Late in 2013, Novartis CEO Joseph Jimenez was considering whether or how to deepen the company's investment in Arogya Parivar, its profitable program that sold Novartis medicines in rural India while expanding access to medicine and health information to millions of... View Details
      Keywords: Shared Value; India; Kenya; Vietnam; Novartis; Arogya Parivar; Social Business; Multinational Firms and Management; Competitive Advantage; Corporate Social Responsibility and Impact; Pharmaceutical Industry; Viet Nam; Kenya; India
      Citation
      Educators
      Purchase
      Related
      Porter, Michael E., Mark R. Kramer, and David Lane. "Social Business at Novartis: Arogya Parivar." Harvard Business School Case 715-411, December 2014. (Revised October 2017.)
      • October 2014 (Revised July 2016)
      • Supplement

      Gilead: Hepatitis C Access Strategy (B)

      By: V. Kasturi Rangan
      While the "Gilead: Hepatitis-C Access Strategy (A)" case (HBS No. 515-025) poses questions on what the company should do with respect to hard-hit countries like Egypt and India, the (B) case provides the answer. In both cases, the company chose to pursue a proactive... View Details
      Keywords: Emerging Markets; Pharmaceutical Industry; Pharmaceutical Industry
      Citation
      Purchase
      Related
      Rangan, V. Kasturi. "Gilead: Hepatitis C Access Strategy (B)." Harvard Business School Supplement 515-044, October 2014. (Revised July 2016.)
      • October 2014 (Revised April 2023)
      • Case

      Gilead: Hepatitis C Access Strategy (A)

      By: V. Kasturi Rangan, Vikram Rangan and David E. Bloom
      Gilead had come up with an innovative drug for Hepatitis C, which affected 180 million people worldwide. The drug was priced at $1,000 a pill for the US market. Gilead had to decide how to price and market the pill in developing countries that bore the brunt of the... View Details
      Keywords: Healthcare; Pharmaceuticals; Pricing; Access To Care; Emerging Markets; Health Care and Treatment; Price; Strategy; Ethics; Pharmaceutical Industry; Pharmaceutical Industry
      Citation
      Educators
      Purchase
      Related
      Rangan, V. Kasturi, Vikram Rangan, and David E. Bloom. "Gilead: Hepatitis C Access Strategy (A)." Harvard Business School Case 515-025, October 2014. (Revised April 2023.)
      • October 2014 (Revised May 2017)
      • Teaching Note

      Pfizer and AstraZeneca: Marketing an Acquisition (A) & (B)

      By: John A. Quelch
      Keywords: Mergers & Acquisitions; Pharmaceutical Companies; Economic Impact Of Mergers; Mergers Impact On International Economies; Impact On Consumers Of Mergers; Customers; Economics; Marketing; Planning; Strategy; Pharmaceutical Industry; Europe; North and Central America
      Citation
      Purchase
      Related
      Quelch, John A. "Pfizer and AstraZeneca: Marketing an Acquisition (A) & (B)." Harvard Business School Teaching Note 515-047, October 2014. (Revised May 2017.)
      • September 2014 (Revised February 2015)
      • Case

      Pfizer and AstraZeneca: Marketing an Acquisition (A)

      By: John A. Quelch and James Weber
      In 2014, Pfizer proposed a friendly acquisition of AstraZeneca, but the AstraZeneca board resisted over price and strategy concerns. Was this good for pharmaceutical consumers? Pfizer, like pharmaceutical companies in general, faced difficulties in growing sales due to... View Details
      Keywords: Health Care Policy; Mergers And Acquisitions; Marketing; Government Relations; Crisis Management; Decision Making; Growth and Development; Management; Markets; Strategy; Pharmaceutical Industry; United Kingdom; United States
      Citation
      Educators
      Purchase
      Related
      Quelch, John A., and James Weber. "Pfizer and AstraZeneca: Marketing an Acquisition (A)." Harvard Business School Case 515-007, September 2014. (Revised February 2015.)
      • September 2014
      • Case

      Pfizer's Centers for Therapeutic Innovation (CTI)

      By: Gary Pisano, James Weber and Kait Szydlowski
      In 2010, Pfizer established four small research units in New York, Boston, San Francisco, and San Diego located close to several premier Academic Medical Centers (AMCs), or hospitals with adjoining medical schools. The goal of these units was to redesign collaboration... View Details
      Keywords: Drug Development; Academic Collaboration; Research And Development; Innovation; Translational Research; Management; Operations; Problems and Challenges; Research; Science; Information Technology; Strategy; Pharmaceutical Industry; Pharmaceutical Industry; North and Central America; Europe; Asia
      Citation
      Educators
      Purchase
      Related
      Pisano, Gary, James Weber, and Kait Szydlowski. "Pfizer's Centers for Therapeutic Innovation (CTI)." Harvard Business School Case 615-024, September 2014.
      • July 2014 (Revised February 2015)
      • Teaching Note

      Johnson & Johnson: The Promotion of Wellness

      By: John A. Quelch
      The chief medical officer of Johnson & Johnson (J & J) is reflecting on forty years of sustained efforts by the company to improve employee wellness. The case reviews J & J's multiple wellness initiatives and efforts to measure their effectiveness. It also invites... View Details
      Keywords: Empoylee Wellness Programs; Human Resource Management; Corporate Management Strategy; Employee Engagement; Human Resources; Management; Organizations; Performance; Personal Development and Career; Programs; Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; North and Central America; Europe; Asia
      Citation
      Purchase
      Related
      Quelch, John A. "Johnson & Johnson: The Promotion of Wellness." Harvard Business School Teaching Note 515-021, July 2014. (Revised February 2015.)
      • May 2014
      • Article

      Right Up the Middle: How Israeli Firms Go Global

      By: Jonathan Friedrich, Amit Noam and Elie Ofek
      The article considers international business enterprises based in Israel and how they successfully expanded from their origins as small businesses. A common technique of those companies in which they focused on market entry in other countries whose markets were too... View Details
      Keywords: Globalized Firms and Management; Israel
      Citation
      Find at Harvard
      Read Now
      Related
      Friedrich, Jonathan, Amit Noam, and Elie Ofek. "Right Up the Middle: How Israeli Firms Go Global." Harvard Business Review 92, no. 5 (May 2014): 113–117.
      • April 2014 (Revised July 2015)
      • Case

      Sanofi Pasteur: The Dengue Vaccine Dilemma

      By: V. Kasturi Rangan, David E. Bloom, Vincent Dessain and Emilie Billaud
      In 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a... View Details
      Keywords: Health Testing and Trials; Product Launch; Market Entry and Exit; Emerging Markets; Pharmaceutical Industry; France
      Citation
      Educators
      Purchase
      Related
      Rangan, V. Kasturi, David E. Bloom, Vincent Dessain, and Emilie Billaud. "Sanofi Pasteur: The Dengue Vaccine Dilemma." Harvard Business School Case 514-074, April 2014. (Revised July 2015.)
      • 2014
      • Working Paper

      The Organizational and Geographic Drivers of Absorptive Capacity: An Empirical Analysis of Pharmaceutical R&D Laboratories

      By: Francesca Lazzeri and Gary P. Pisano
      Scholars and practitioners alike now recognize that a firm's capacity to assimilate and use know-how from external sources—what Cohen and Levinthal (1990) called "absorptive capacity"—plays a central role in innovation performance. In recent years, a common strategy... View Details
      Keywords: Geographic Location; Industry Clusters; Knowledge Acquisition; Pharmaceutical Industry; San Francisco; San Diego; Massachusetts
      Citation
      SSRN
      Read Now
      Related
      Lazzeri, Francesca, and Gary P. Pisano. "The Organizational and Geographic Drivers of Absorptive Capacity: An Empirical Analysis of Pharmaceutical R&D Laboratories." Harvard Business School Working Paper, No. 14-098, April 2014.
      • Spring 2014
      • Article

      Attracting Long-Term Investors Through Integrated Thinking and Reporting: A Clinical Study of a Biopharmaceutical Company

      By: Andrew Knauer and George Serafeim
      Faced with a large percentage of investors that chase short-term returns, companies could benefit by attracting investors with longer-term horizons and incentives that are more consistent with the long-term strategy of the company. The managers of most companies take... View Details
      Keywords: Investing; Asset Management; Long-term Investing; Short-termism; Sustainability; Integrated Reporting; Leadership & Corporate Accountability; Pharmaceuticals; Leadership; Integrated Corporate Reporting; Investment; Business and Stakeholder Relations; Corporate Finance; Pharmaceutical Industry; Pharmaceutical Industry
      Citation
      Find at Harvard
      Purchase
      Related
      Knauer, Andrew, and George Serafeim. "Attracting Long-Term Investors Through Integrated Thinking and Reporting: A Clinical Study of a Biopharmaceutical Company." Journal of Applied Corporate Finance 26, no. 2 (Spring 2014): 57–64.
      • March 2014 (Revised December 2014)
      • Case

      Vision 2020: Takeda and the Vaccine Business

      By: John A. Quelch and Margaret L. Rodriguez
      In 2014, Yasuchika Hasegawa was orchestrating the transformation of Takeda from a Japanese pharmaceutical company with a global footprint into a global company with a Japanese heritage. A 33-year veteran of Takeda, Hasegawa-san was appointed president of Takeda in 2003... View Details
      Keywords: Health Care; Global; NGO; Public Health; Japan; GSK; Vaccine; Supply Chain; Market Entry; Health; Health Care and Treatment; Trade; Market Entry and Exit; Global Strategy; Pharmaceutical Industry; Pharmaceutical Industry
      Citation
      Educators
      Purchase
      Related
      Quelch, John A., and Margaret L. Rodriguez. "Vision 2020: Takeda and the Vaccine Business." Harvard Business School Case 514-084, March 2014. (Revised December 2014.)
      • March 2014
      • Case

      Novartis' Sandoz: Between Generics and Pharma

      By: Krishna Palepu and Carin-Isabel Knoop
      Sandoz, which made a significant investment in bio-similars as a way to differentiate itself from its generic drug industry peers, has to negotiate with its parent company and the innovative pharma division on how best to commercialize its bio-similar portfolio. What... View Details
      Keywords: Global Strategy And Leadership; Managing Within A Multi-Business Organization; Generic Pharmaceuticals; Global Strategy
      Citation
      Educators
      Purchase
      Related
      Palepu, Krishna, and Carin-Isabel Knoop. "Novartis' Sandoz: Between Generics and Pharma." Harvard Business School Case 114-033, March 2014.
      • January 2014 (Revised January 2014)
      • Supplement

      GlaxoSmithKline in China (C)

      By: John Quelch and Margaret L. Rodriguez
      Keywords: China; Healthcare; Pharmaceutical Sales; Ethics; Multinational Firms and Management; Pharmaceutical Industry; China
      Citation
      Purchase
      Related
      Quelch, John, and Margaret L. Rodriguez. "GlaxoSmithKline in China (C)." Harvard Business School Supplement 514-092, January 2014. (Revised January 2014.) (This case is a follow up to GlaxoSmithKline (A), 514049 and GlaxoSmithKline (B), 514050.)
      • ←
      • 7
      • 8
      • …
      • 15
      • 16
      • →

      Are you looking for?

      →Search All HBS Web
      ǁ
      Campus Map
      Harvard Business School
      Soldiers Field
      Boston, MA 02163
      →Map & Directions
      →More Contact Information
      • Make a Gift
      • Site Map
      • Jobs
      • Harvard University
      • Trademarks
      • Policies
      • Accessibility
      • Digital Accessibility
      Copyright © President & Fellows of Harvard College.